Mark L. Rohrbaugh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark L. Rohrbaugh has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
A. Mackay-Sim
1 shared publicationA. Zarzeczny
1 shared publicationA.E. Willing
1 shared publicationAnn M. Hammersla
Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Rockville, MD 20852,USA
1 shared publication- Anthony Atala
Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, North Carolina, USA
1 shared publication Anujith Kumar
Stamcel Instituut Leuven, Katholieke Universiteit Leuven, Leuven 3000, Belgium
1 shared publication
Latest Publications
- 31 January 2014
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 14 (3) , 326-329
Leveraging Public Private Partnerships to Innovate under Challenging Budget Times
The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.
- 31 January 2014
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 14 (3) , 326-329
Leveraging Public Private Partnerships to Innovate under Challenging Budget Times
The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.
- 1 January 2012
- Published by Elsevier
Contributor contact details